PHD1 regulates p53-mediated colorectal cancer chemoresistance

Overcoming resistance to chemotherapy is a major challenge in colorectal cancer (CRC) treatment, especially since the underlying molecular mechanisms remain unclear. We show that silencing of the prolyl hydroxylase domain protein PHD1, but not PHD2 or PHD3, prevents p53 activation upon chemotherapy...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:EMBO Mol Med
Egile Nagusiak: Deschoemaeker, Sofie, Di Conza, Giusy, Lilla, Sergio, Martín-Pérez, Rosa, Mennerich, Daniela, Boon, Lise, Hendrikx, Stefanie, Maddocks, Oliver DK, Marx, Christian, Radhakrishnan, Praveen, Prenen, Hans, Schneider, Martin, Myllyharju, Johanna, Kietzmann, Thomas, Vousden, Karen H, Zanivan, Sara, Mazzone, Massimiliano
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: John Wiley & Sons, Ltd 2015
Gaiak:
Research Articles
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4604688/
https://ncbi.nlm.nih.gov/pubmed/26290450
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.15252/emmm.201505492
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak